Outlook Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in trillions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Outlook Therapeutics, Inc. (OTLK) - Annual data in trillions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018
Operating Activities
Net Income-62.420.000.000.000.000.000.000.00
Depreciation & Amortization0.120.000.000.000.000.000.000.00
Stock Based Compensation8.900.000.000.000.000.000.000.00
Change in Working Capital0.000.000.000.000.000.000.000.00
Change in Accounts Receivable0.000.000.000.000.000.000.000.00
Change in Inventory0.000.000.000.000.000.000.000.00
Change in Accounts Payable0.000.000.000.000.000.000.000.00
Change in Other Working Capital0.000.000.000.000.000.000.000.00
Other Operating Activities1.580.000.000.000.000.000.000.00
Net Cash from Operating Activities-51.830.000.000.000.000.000.000.00
Investing Activities
Capital Expenditures0.000.000.000.000.000.000.000.00
Acquisitions0.000.000.000.000.000.000.000.00
Net Cash from Investing Activities0.000.000.000.000.000.000.000.00
Financing Activities
Debt Repayment0.000.000.000.000.000.000.000.00
Common Stock Issued0.000.000.000.000.000.000.000.00
Other Financing Activities44.980.000.000.000.000.000.000.00
Net Cash from Financing Activities44.980.000.000.000.000.000.000.00
Summary
Net Change in Cash-6.840.000.000.000.000.000.000.00
Cash at Beginning of Period14.930.000.000.000.000.000.000.00
Cash at End of Period8.080.000.000.000.000.000.000.00
Free Cash Flow-51.830.000.000.000.000.000.000.00
Supplemental Disclosures
Interest Paid0.000.000.000.000.000.000.000.00